Skip to main content

Advertisement

Table 3 Expression of e2f-1 and its correlation with clinicopathological parameters in 121 cases

From: Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma

Parameters Grouping n e2f-1 [case (%)] χ2test
Positive Negative χ2value P value
Age (year) <60 40 17(42.5) 23(57.5) 0.336 0.562
≥60 81 30(37.0) 51(63.0)   
Gender Male 77 32(41.6) 45(58.4) 0.657 0.418
Female 44 15(34.1) 29(65.9)   
Tumor diameter (cm) <5 48 27(56.3) 21(43.7) 10.148 0.001
≥5 73 20(23.4) 53(76.6)   
Location of tumor Cardia, fundus 20 7(35.0) 13(65.0) 0.226 0.893
Body 37 14(37.8) 23(62.2)   
Pylorus, antrum 64 26(60.6) 38(59.4)   
Lauren classification Intestinal 84 36(42.9) 48(57.1) 1.863 0.172
Diffuse 37 11(29.7) 26(70.3)   
Histological type Grade 1 25 10(40.0) 15(60.0) 0.236 0.889
Grade 2 47 17(36.2) 30(63.8)   
Grade 3 49 20(40.8) 29(59.2)   
Invasion depth T1 18 12(66.7) 6(33.3) 14.143 0.003
T2 32 17(53.1) 15(46.9)   
T3 30 7(23.3) 23(76.7)   
T4 41 11(26.8) 30(73.2)   
Metastatic lymph node ratio <35% 60 30(50.0) 30(50.0) 6.237 0.013
≥35% 61 17(27.9) 44(72.1)   
Involving lymph node station N0 43 21(48.8) 22(51.2) 6.739 0.081
N1 41 17(41.5) 24(58.5)   
N2 26 8(30.8) 18(69.2)   
N3 11 1(9.1) 10(90.91)   
TNM stages Ia 16 10(62.5) 6(37.5) 13.724 0.017
Ib 17 8(47.1) 9(52.9)   
II 20 11(55.0) 9(45.0)   
IIIa 20 8(40.0) 12(60.0)   
IIIb 22 6(27.3) 16(72.7)   
IV 26 7(26.9) 19(73.1)   
Survival (month) <20 75 52(69.3) 23(30.7) 10.356 0.005
≥20 46 20/(43.5) 26/(56.5)